Targeted Oncology: Expert highlights benefits of Fedratinib in subgroup of patients with myelofibrosis

Dr. Ruben Mesa, director of the Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, discussed the benefits of Fedratinib (Inrebic) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis.

Read the full story

Share This Article!